Adjuvant Stereotactic Body Radiation Therapy After Trans-arterial Chemoembolization in Hepatocell… (NCT04996914) | Clinical Trial Compass
RecruitingNot Applicable
Adjuvant Stereotactic Body Radiation Therapy After Trans-arterial Chemoembolization in Hepatocellular Carcinoma
Germany30 participantsStarted 2026-05-05
Plain-language summary
The study investigates the adjuvant SBRT following TACE in early and intermediate stages HCC not amenable for surgical resection.
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* HCC (diagnosis: histological or radiological)
* Age: 18-80
* Number of lesions 1-3 lesions
* Size of the lesion (or sum of 2-3 lesions) ≥ 4 cm
* Sufficient non-tumorous liver volume (≥ 800 cm3)
* Child Pugh Score: A5-6 or B7-8
* BCLC A or B
* Patient is illegible or refused surgical resection or orthotopic liver transplant
* Blood work (within 2 weeks before registration):
* Absolute neutrophil count (ANC) ≥ 1,500 cells/mm³)
* Platelets ≥50,000 cells/mm³
* AST (and ALT) \< 5 times ULN
* Serum creatinine ≤ ULN or creatinine clearance ≥ 50 mL/min
Exclusion Criteria:
* Evidence of extrahepatic disease (lymph node or distant metastases)
* Evidence of macroscopic vascular invasion
* Evidence of an arterio-portal or arterio-venous fistulas
* History of previous malignancy
* Previous SIRT
* Previous Sorafenib in the last 8 weeks
* Pregnant and lactating females